Search
for
Sort by
Research 601–630 of 1000+
- 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
- Research progress in the treatment of non-scarring alopecia: mechanism and treatment
- Advances in the treatment of male androgenetic alopecia: current options and emerging therapies
- Small Molecule Agents Against Alopecia: Potential Targets and Related Pathways
- 1094 Discovering hair loss treatments that increase the Wnt/β-catenin signaling pathway by high-throughput screening
- An Analysis on Whether or Not Baldness Can Be Reversed
- Biotechnology in Hair Care (II): Growth Modulation
- Propecia<sup>®</sup> Use in Patients Receiving Hair Transplantation
- TREATMENT OF HAIR LOSS
- Relative efficacy of microneedling in the treatment of pattern hair loss: a protocol for a systematic review with network meta-analysis
- 370 An analysis of androgenetic alopecia treatment content on Instagram and TikTok
- Novel drugs of United States Food and Drug Administration approved in 2024
- Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data
- Androgenetic Alopecia: An Update of Treatment Options
- The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
- Medical Treatment of Hair Loss
- What's New: Newly Approved Drugs for Children
- Testosterone Therapy in Women: A Literature Review of Clinical Indications, Dosing, Routes of Administration, and Safety
- A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System
- FDA declines approval of testosterone drug for third time
- FDA declines approval of testosterone drug for third time
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss
- Lilly arthritis drug approved for alopecia
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
- DRUG NEWS
- Exploring novel management options for alopecia areata
- PHARMACOTHERAPY ALOPECIA ANDROGENETIC IN MEN